Cite
HARVARD Citation
Anderson, K. et al. (2022). Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy. Journal for immunotherapy of cancer. 10 (3), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Anderson, K. et al. (2022). Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy. Journal for immunotherapy of cancer. 10 (3), p. . [Online].